Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087698 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT00087698 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 77 participants.
The verdict
NCT00087698, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
This study aims to determine how successful the chemotherapy regimen of Pemetrexed plus cisplatin before surgery is at killing all the tumor so that none is left at the time of surgery. Following surgery, all eligible patients will receive radiation to the chest. How patients respond, whether the cancer returns and if so, where, will also be monitored.
Interventions
- DRUG cisplatin
- DRUG pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2003-09 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087698
The ClinicalTrials.gov registry entry for NCT00087698 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cisplatin is the first listed.
NCT00087698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00087698 about?
NCT00087698 is a clinical study titled "Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma". This study aims to determine how successful the chemotherapy regimen of Pemetrexed plus cisplatin before surgery is at killing all the tumor so that none is left at the time of surgery. Following surgery, all eligible patients will receive radiation to the chest. How patients respond, whether the ca...
What is the current status of trial NCT00087698?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2003-09. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00087698?
The interventions under investigation include: cisplatin (DRUG), pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00087698?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.